Drug Shortage Report for INCRUSE ELLIPTA
| Report ID | 178691 |
| Drug Identification Number | 02423596 |
| Brand name | INCRUSE ELLIPTA |
| Common or Proper name | umeclidinium (as bromide) dry powder for oral inhalation |
| Company Name | GLAXOSMITHKLINE INC |
| Market Status | MARKETED |
| Active Ingredient(s) | UMECLIDINIUM |
| Strength(s) | 62.5MCG |
| Dosage form(s) | POWDER |
| Route of administration | INHALATION INHALATION |
| Packaging size | 1x30 |
| ATC code | R03BB |
| ATC description | |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2022-12-12 |
| Estimated end date | 2023-01-06 |
| Actual end date | 2023-01-03 |
| Shortage status | Resolved |
| Updated date | 2023-01-04 |
| Company comments | Managing supply due to high demand. |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | 1-800-387-7374 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2023-01-04 | French | Compare |
| v3 | 2023-01-04 | English | Compare |
| v2 | 2022-12-16 | French | Compare |
| v1 | 2022-12-16 | English | Compare |
Showing 1 to 4 of 4